Pharmacokinetics and Hepatic Safety of EGCG

Conditions

Diseases of the Digestive System - Liver | Women's Health

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

A trial to assess the pharmacokinetics and hepatic safety of EGCG in women with and without uterine fibroids.

Ages
18 years - 40 years
Gender
Female only

Find out more about who can participate in this trial

Trial with
National Institute of Child Health and Human Development (NICHD)
Start Date
07/08/2021
End Date
04/30/2021

For more information about this study, contact:

Luisa Coraluzzi

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Hugh Taylor, MD
Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology; Chair, Obstetrics, Gynecology & Reproductive Sciences; Chief of Obstetrics and Gynecology, Yale-New Haven Hospital

Sub-Investigators

Last Updated
11/17/2021
Study HIC
#2000028370

Pharmacokinetics and Hepatic Safety of EGCG

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information